JPH0614996A - Adsorption module - Google Patents
Adsorption moduleInfo
- Publication number
- JPH0614996A JPH0614996A JP5125421A JP12542193A JPH0614996A JP H0614996 A JPH0614996 A JP H0614996A JP 5125421 A JP5125421 A JP 5125421A JP 12542193 A JP12542193 A JP 12542193A JP H0614996 A JPH0614996 A JP H0614996A
- Authority
- JP
- Japan
- Prior art keywords
- housing
- inorganic hollow
- adsorption
- hollow fibers
- adsorption module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 28
- 239000012510 hollow fiber Substances 0.000 claims abstract description 32
- 210000001124 body fluid Anatomy 0.000 claims abstract description 14
- 239000010839 body fluid Substances 0.000 claims abstract description 14
- 239000003446 ligand Substances 0.000 claims abstract description 10
- 229910010272 inorganic material Inorganic materials 0.000 claims abstract description 3
- 239000011147 inorganic material Substances 0.000 claims abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000011324 bead Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000002502 anti-myelin effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、自己免疫疾患患者の治
療用に使用される吸着モジュ−ルの改良に関するもの
で、特に無機質中空糸をハウジング内に装填し、除去物
質の吸着効率を向上させた吸着モジュ−ルを提供するも
のである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an improvement of an adsorption module used for treating patients with autoimmune diseases, and in particular, an inorganic hollow fiber is loaded in a housing to improve the adsorption efficiency of a substance to be removed. And an adsorption module for the same.
【０００２】[0002]
【従来技術及び発明が解決しようとする課題】現在、吸
着モジュ−ルは、ビ−ズ表面に担体をコ−ティングしこ
れらをカラムに充填したものや、合成（または天然）繊
維からなる中空糸と担体をコ−ティングしたビ−ズを一
つのハウジング内に充填したものが使用されている。2. Description of the Related Art At present, an adsorption module is a hollow fiber composed of synthetic (or natural) fibers obtained by coating a carrier on the bead surface and packing them in a column. A single housing is filled with beads coated with a carrier.
【０００３】しかしながら前者では、血液、血漿等の体
液の流れが阻害されやすく、ビ−ズの表面積は大きいに
もかかわらず十分に機能を発揮できなかった。このため
後者のように体液の流れを確保するために中空糸を装填
し、ビ−ズで除去物質の吸着効果を高めるようにしてい
るが、ビ−ズ状の吸着剤では、吸着モジュ−ルとして組
み立てた後、製品として運搬する途中でおたがいの摩擦
により、微小塊が発生するので、これを捕捉するための
フィルタ−を新たに装着しなければならずコスト高にな
っていた。そこで本発明は、以上の課題を解決するため
に鋭意検討を重ねた結果次の発明に到達した。However, in the former case, the flow of body fluids such as blood and plasma is liable to be impeded, and although the beads have a large surface area, they cannot sufficiently exhibit their functions. For this reason, as in the latter case, hollow fibers are loaded in order to secure the flow of body fluid, and the bead-like adsorbent is used to enhance the adsorbing effect of the substance to be removed. After assembling as described above, minute lumps are generated due to friction of each other in the course of transportation as a product, and a filter for capturing this is required to be newly attached, resulting in high cost. Therefore, the present invention has reached the following invention as a result of intensive studies to solve the above problems.
【０００４】[0004]
【課題を解決するための手段】本発明は、リガンドをコ
−ティングした無機材料よりなる中空糸３（以下「無機
質中空糸３」）がハウジング２内に装填され、該ハウジ
ング２の端部に体液の出口７を有するキャップ９と体液
の入口６を有するキャップ５を多数の孔８を有するスト
ッパ−４を介在させて装着した吸着モジュ−ル１を提供
するものである。According to the present invention, a hollow fiber 3 made of an inorganic material coated with a ligand (hereinafter referred to as "inorganic hollow fiber 3") is loaded into a housing 2, and the end portion of the housing 2 is filled with the hollow fiber 3. The adsorption module 1 is provided in which a cap 9 having a body fluid outlet 7 and a cap 5 having a body fluid inlet 6 are mounted via a stopper 4 having a large number of holes 8.
【０００５】[0005]
【作用】体液の入口６から無機質中空糸３内に導入され
た体液は流路を妨げられることなくスム−ズに無機質中
空糸３内を流れ体液の出口７より排出される。体液中の
除去物質は無機質中空糸３内を流れる途中でリガンドに
吸着除去される。The body fluid introduced from the body fluid inlet 6 into the inorganic hollow fiber 3 smoothly flows through the inorganic hollow fiber 3 without being obstructed in the flow path and is discharged from the body fluid outlet 7. The removed substance in the body fluid is adsorbed and removed by the ligand while flowing through the inorganic hollow fiber 3.
【０００６】[0006]
【実施例】図１は本発明の吸着モジュ−ル１の概略図で
ある。吸着モジュ−ル１は、図２に示すようなリガンド
を内面と外面にコ−ティングした複数の無機質中空糸３
をハウジング２内に装填している。1 is a schematic view of an adsorption module 1 of the present invention. The adsorption module 1 comprises a plurality of inorganic hollow fibers 3 coated with ligands on the inner and outer surfaces as shown in FIG.
Are loaded in the housing 2.
【０００７】ハウジング２の端部には図３に示すように
らせん状の凸部１０を形成した大径の接続部１１が形成
され、これに図４に示すような多数の孔８を有する網目
状のストッパ−４を介在させて、図５に示すような体液
の入口６（出口７）を有し前記らせん状の凸部１０に対
応するらせん状の凹部１２が形成されたキャップ５
（９）が装着される。As shown in FIG. 3, a large-diameter connecting portion 11 having a spiral convex portion 10 is formed at the end of the housing 2, and a mesh having a large number of holes 8 as shown in FIG. A cap 5 having a body fluid inlet 6 (outlet 7) as shown in FIG. 5 and a spiral concave portion 12 corresponding to the spiral convex portion 10 formed with a stopper 4 interposed therebetween.
(9) is attached.
【０００８】本発明に使用されるリガンドは、生物学的
吸着剤として、例えばプロテインＡ（ＩｇＧ、抗血小板
抗体）、第９因子（抗第９因子抗体）、オリゴ糖（抗
Ａ、Ｂ抗体）、シビレエイ／α１８３−２００（抗Ａｃ
ｈＲ抗体）、シビレエイ／α１２８−１４２（抗Ａｃｈ
Ｒ抗体）、抹消性ミエリン／Ｐ2 蛋白の６６−７８残基
（抗ミエリン抗体）、抗ＬＤＬ抗体（ＬＤＬコレステロ
−ル）、抗ビリルビンＭＡｂ（ビリルビン）等が使用で
きる（（ ）内は除去物質）。また物理学的吸着剤とし
て、デキストラン硫酸（ＬＤＬコレステロ−ル、抗ＤＮ
Ａ抗体、抗カルジオリピン抗体）、フェニルアラニン
（免疫複合体、抗ＤＮＡ抗体）、４級アンモニウムクロ
ライド（ビリルビン、胆汁酸）、トリプトファン（抗Ａ
ｃｈＲ抗体）、ポリエステル不織布（リンパ球）、スル
ファチゾ−ル（抗ＡｃｈＲ抗体、βリンパ球）、ＭＭＡ
−ＤＶＢ（β2 ミクログロブリン）、ｏｒｇａｎｉｃ
ｃｏｍｐｏｕｎｄ（β2 ミクログロブリン）、ＨＭＤＩ
（β2 ミクログロブリン）、ＴＰ、ＲＣＡ（ＣＤ４、Ｃ
Ｄ８細胞）等が使用できる（（ ）内は除去物質）。The ligand used in the present invention is a biological adsorbent, for example, protein A (IgG, anti-platelet antibody), factor 9 (anti-factor 9 antibody), oligosaccharide (anti-A, B antibody). , Torpedo / α183-200 (anti-Ac
hR antibody), Torpedo / α128-142 (anti-Ach
R antibody), 66-78 residues of peripheral myelin / P 2 protein - in (anti myelin antibody), an anti-LDL antibody (LDL cholesterol Le), anti-bilirubin MAb (bilirubin), and the like can be used (() is removing material ). As a physical adsorbent, dextran sulfate (LDL cholesterol, anti-DN
A antibody, anti-cardiolipin antibody), phenylalanine (immune complex, anti-DNA antibody), quaternary ammonium chloride (bilirubin, bile acid), tryptophan (anti-A)
chR antibody), polyester non-woven fabric (lymphocyte), sulfatizole (anti-AchR antibody, β lymphocyte), MMA
-DVB (β 2 microglobulin), organic
compound (β 2 microglobulin), HMDI
(Β 2 microglobulin), TP, RCA (CD4, C
D8 cells) and the like can be used (removed substances in ()).
【０００９】また無機質中空糸３は、ガラス、セラミッ
ク等から構成され、内径が２００μ〜５４０μのものを
使用するのが好ましい。内径が２００μ以下では径が小
さすぎて体液の流量が充分に確保できないので好ましく
ない。また、内径が５４０μ以上では、径が大きすぎて
ハウジングの単位容積内に充填できる無機質中空糸３の
本数が少なくなりひいては無機質中空糸３の表面にコ−
ティングした吸着性能を有するリガンドの表面積が小さ
くなり吸着効率を充分に発揮できないので好ましくな
い。無機質中空糸３は、多孔質のもののほうが表面積が
より大となり吸着性能が向上するのでより好ましい。The inorganic hollow fiber 3 is preferably made of glass, ceramics or the like and has an inner diameter of 200 to 540 μ. If the inner diameter is 200 μm or less, the diameter is too small to ensure a sufficient flow rate of body fluid, which is not preferable. Further, when the inner diameter is 540 μm or more, the diameter is too large and the number of the inorganic hollow fibers 3 that can be filled in the unit volume of the housing is small, and as a result, the surface of the inorganic hollow fibers 3 is coated.
It is not preferable because the surface area of the ligand having the adsorbed adsorption property becomes small and the adsorption efficiency cannot be sufficiently exhibited. The inorganic hollow fiber 3 is more preferably porous because the surface area is larger and the adsorption performance is improved.
【００１０】リガンドを無機質中空糸３に結合させる手
段としては、公知の手段によりスペ−サ−を介して行う
ことができる。例えばアミノアルキル基を有する無機質
中空糸３に結合試薬として、水溶性カルボジイミド類
（例えば、１−エチル−３−（３−ジメチルアミノプロ
ピル）カルボジイミド・塩酸、１−シクロヘキシル−３
−（２−モルホリンエチル）カルボジイミドメト−ｐ−
トルエン−スルホン酸塩等）を用いて、前記アミノアル
キル基にリガンドを反応させて結合する方法などが挙げ
られる（この場合はアミノアルキル基と結合試薬がスペ
−サ−の役割を果たす）。反応温度、反応時間は特に限
定されない。As a means for binding the ligand to the inorganic hollow fiber 3, a known means can be used via a spacer. For example, as a binding reagent for the inorganic hollow fiber 3 having an aminoalkyl group, water-soluble carbodiimides (for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydrochloric acid, 1-cyclohexyl-3
-(2-morpholineethyl) carbodiimidemetho-p-
(Toluene-sulfonate, etc.) and the like, a method of reacting a ligand with the above-mentioned aminoalkyl group and binding the same (in this case, the aminoalkyl group and the binding reagent function as a spacer). The reaction temperature and reaction time are not particularly limited.
【００１１】ハウジング２内に充填される無機質中空糸
３の本数、内径の大きさは、ストッパ−４の孔８の数、
大きさを適宜変更することにより調整することができ
る。ストッパ−４の孔８は、無機質中空糸３の外径より
も細孔にすることにより無機質中空糸３の端部をより確
実に固定することができる。The number of the inorganic hollow fibers 3 filled in the housing 2 and the size of the inner diameter are the number of the holes 8 of the stopper-4,
It can be adjusted by appropriately changing the size. The hole 8 of the stopper-4 can be more reliably fixed to the end portion of the inorganic hollow fiber 3 by making the hole smaller than the outer diameter of the inorganic hollow fiber 3.
【００１２】本発明の吸着モジュ−ル１は、無機質中空
糸３をハウジング２内に装填した後、これらの両端部に
ストッパ−４を介在させてキャップ５（９）を装着する
ことにより組み立てられる。The adsorption module 1 of the present invention is assembled by loading the inorganic hollow fibers 3 in the housing 2 and then attaching the caps 5 (9) with stoppers 4 interposed at both ends thereof. .
【００１３】表面にリガンドとしてオリゴ糖をコ−ティ
ングした内径２００μ、長さ２８０ｍｍのガラス製の無
機質中空糸３を１０，０００本ハウジング２内に装填し
た吸着モジュ−ルを作成し、これに血液を通して除去物
質の吸着効率等を確認したところ従来のビ−ズを用いた
吸着モジュ−ルよりも抗Ａ、Ｂ抗体の吸着効率が２０％
以上向上し良好な結果が得られた。An adsorption module was prepared by loading 10,000 glass-made inorganic hollow fibers 3 having an inner diameter of 200 μm and a length of 280 mm coated on the surface with oligosaccharides as a ligand into a housing 2, and blood was applied to the adsorption module. The adsorption efficiency of the removed substance was confirmed through 20%, and the adsorption efficiency of the anti-A and B antibodies was 20% as compared with the conventional adsorption module using beads.
The above results were improved and good results were obtained.
【００１４】[0014]
【発明の効果】 無機質中空糸３は、患者の疾患等に応じてハウジング
内に装填する本数、内径等を適宜選択することができる
ので種々の吸着モジュ−ルを提供することができる。 血液の流れがスム−ズになるので吸着効率が向上す
る。 従来のビ−ズを使用する場合のように、微小塊が生じ
ないので、血液流路の途中に特殊フィルタ−を設ける必
要がなくコストダウンが図れる。 無機質中空糸３は、ハウジング２から容易に取りはず
して洗浄、回収でき再使用可能である。EFFECTS OF THE INVENTION Since the number of the inorganic hollow fibers 3 to be loaded into the housing, the inner diameter, etc. can be appropriately selected according to the patient's disease or the like, various adsorption modules can be provided. Since the blood flow becomes smooth, the adsorption efficiency is improved. As in the case of using a conventional bead, since no minute mass is generated, it is not necessary to provide a special filter in the middle of the blood flow path, and the cost can be reduced. The inorganic hollow fiber 3 can be easily removed from the housing 2, washed, collected, and reused.
【図１】本発明の吸着モジュ−ルの概略図FIG. 1 is a schematic view of an adsorption module of the present invention.
【図２】本発明に使用される無機質中空糸の概略図FIG. 2 is a schematic view of an inorganic hollow fiber used in the present invention.
【図３】吸着モジュ−ルを構成するハウジングの概略図FIG. 3 is a schematic view of a housing that constitutes an adsorption module.
【図４】無機質中空糸の端部を固定するストッパ−の概
略図FIG. 4 is a schematic view of a stopper that fixes the end of the inorganic hollow fiber.
【図５】図３のハウジングの両端部に装着されるキャッ
プの概略図5 is a schematic view of caps attached to both ends of the housing of FIG.
１ 吸着モジュ−ル ６ 血
液入口 ２ ハウジング ７ 血
液出口 ３ 無機質中空糸 ８ 孔 ４ ストッパ− ５ キャップ1 Adsorption Module 6 Blood Inlet 2 Housing 7 Blood Outlet 3 Inorganic Hollow Fiber 8 Hole 4 Stopper 5 Cap
Claims (1)
りなる中空糸３（以下「無機質中空糸３」）がハウジン
グ２内に装填され、該ハウジング２の端部に体液の出口
７を有するキャップ９と体液の入口６を有するキャップ
５を多数の孔８を有するストッパ−４を介在させて装着
したことを特徴とする吸着モジュ−ル１。1. A cap 9 having a hollow fiber 3 made of an inorganic material coated with a ligand (hereinafter referred to as "inorganic hollow fiber 3") loaded in a housing 2 and having a body fluid outlet 7 at an end of the housing 2. An adsorption module 1 characterized in that a cap 5 having an inlet 6 for body fluid and a stopper 4 having a large number of holes 8 are attached thereto.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5125421A JPH0614996A (en) | 1992-05-01 | 1993-04-28 | Adsorption module |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4-140047 | 1992-05-01 | ||
| JP14004792 | 1992-05-01 | ||
| JP5125421A JPH0614996A (en) | 1992-05-01 | 1993-04-28 | Adsorption module |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0614996A true JPH0614996A (en) | 1994-01-25 |
Family
ID=26461863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5125421A Pending JPH0614996A (en) | 1992-05-01 | 1993-04-28 | Adsorption module |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0614996A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010158394A (en) * | 2009-01-08 | 2010-07-22 | Kaneka Corp | Immunoglobulin adsorbent excellent in blood compatibility, and adsorption apparatus |
| WO2013047549A1 (en) * | 2011-09-30 | 2013-04-04 | 東レ株式会社 | Purification column and method for manufacturing purification column |
| WO2013129384A1 (en) * | 2012-03-02 | 2013-09-06 | 東レ株式会社 | Adsorption column |
| JP2014210174A (en) * | 2013-04-04 | 2014-11-13 | 東レ株式会社 | Purification column and method of manufacturing the same |
| JP2017080400A (en) * | 2007-08-31 | 2017-05-18 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Selective cellular adsorption removal device and the related method |
-
1993
- 1993-04-28 JP JP5125421A patent/JPH0614996A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017080400A (en) * | 2007-08-31 | 2017-05-18 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Selective cellular adsorption removal device and the related method |
| JP2010158394A (en) * | 2009-01-08 | 2010-07-22 | Kaneka Corp | Immunoglobulin adsorbent excellent in blood compatibility, and adsorption apparatus |
| WO2013047549A1 (en) * | 2011-09-30 | 2013-04-04 | 東レ株式会社 | Purification column and method for manufacturing purification column |
| JPWO2013047549A1 (en) * | 2011-09-30 | 2015-03-26 | 東レ株式会社 | Purification column and purification column manufacturing method |
| EP2762180A4 (en) * | 2011-09-30 | 2015-05-13 | Toray Industries | Purification column and method for manufacturing purification column |
| WO2013129384A1 (en) * | 2012-03-02 | 2013-09-06 | 東レ株式会社 | Adsorption column |
| JP2014210174A (en) * | 2013-04-04 | 2014-11-13 | 東レ株式会社 | Purification column and method of manufacturing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101420992B (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| US5122112A (en) | Antigen-specific removal of circulating immune complexes | |
| EP0868208B1 (en) | Affinity membrane system and method of using same | |
| US4685900A (en) | Therapeutic device | |
| US4714556A (en) | Blood purification | |
| US8921339B2 (en) | Device for bio-affinity material | |
| US6866846B1 (en) | Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation | |
| JPH0614996A (en) | Adsorption module | |
| Yavuz et al. | Immunoadsorption of cholesterol on protein A oriented beads | |
| EP0272792B1 (en) | Antigen-specific removal of circulating immune complexes | |
| CA1236738A (en) | Therapeutic device | |
| JPH08108069A (en) | Separation of stem cell | |
| JPH0622633B2 (en) | Adsorbent and removal device using the same | |
| JPS62192172A (en) | Adsorbing body | |
| JPS59169532A (en) | Adsorbing material of c-reactive protein | |
| CA1309020C (en) | Extracorporeal removal of immunoglobulin-g and circulating immune complexes | |
| US20100098698A1 (en) | Targeted apheresis for the treatment of rheumatoid arthritis | |
| JPH0585191B2 (en) | ||
| Denizli | Autoimmune diseases and immunoadsorption therapy | |
| JP2726662B2 (en) | Adsorbent and removal device using the same | |
| JPH01158970A (en) | Immunoglobulin adsorbing material for direct blood perfusion and adsorbing apparatus | |
| Wang et al. | Chimeric AQP4-based immunosorbent for highly-specific removal of AQP4-IgG from blood | |
| Burgstaler et al. | Immunoabsorption in an extracorporeal plasma perfusion system: in vitro studies | |
| JPH0332740A (en) | Method and kit for producing adsorbent having fixed physiologically active substance | |
| JPS60241450A (en) | Adsorbing material for purifying body fluids |